Comparative Pharmacology
Head-to-head clinical analysis: BOSULIF versus ICLUSIG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSULIF versus ICLUSIG.
BOSULIF vs ICLUSIG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a tyrosine kinase inhibitor that targets BCR-ABL kinase, as well as SRC family kinases. It inhibits the phosphorylation of tyrosine residues in proteins involved in the BCR-ABL signaling pathway, thereby inhibiting cell proliferation and inducing apoptosis in Philadelphia chromosome-positive (Ph+) leukemia cells.
Ponatinib is a multi-targeted tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant form, and also inhibits VEGFR, PDGFR, FGFR, EPH receptors, and SRC family kinases.
400 mg orally once daily with food.
45 mg orally once daily with or without food.
None Documented
None Documented
The terminal elimination half-life is approximately 22.5 hours (range 15-34 hours) following a 500 mg oral dose. This supports once-daily dosing, with steady-state achieved within 15 days.
Terminal elimination half-life is approximately 7.5 hours in healthy subjects, supporting twice-daily dosing.
Primarily fecal (approximately 85% of the administered dose), with renal excretion accounting for less than 1% as unchanged drug and 3% as metabolites. Biliary excretion is a significant route for elimination of unchanged drug and metabolites.
Primarily fecal (91%) as unchanged drug and metabolites; renal elimination accounts for less than 4% of the dose.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor